Supplementary Figure 4 from Activating Inducible T cell Co-stimulator (ICOS) yields anti-tumor activity alone and in combination with anti-PD-1 checkpoint blockade

Uncropped gel images</p

Supplementary Figure 2 from Activating Inducible T cell Co-stimulator (ICOS) yields anti-tumor activity alone and in combination with anti-PD-1 checkpoint blockade

Flow cytometry gating strategy for ICOS on individual T cell populations.</p

Supplementary Figure 12 from Activating Inducible T cell Co-stimulator (ICOS) yields anti-tumor activity alone and in combination with anti-PD-1 checkpoint blockade

Clinical case studies of feladilimab monotherapy and in combination with pembrolizumab.</p

Supplementary Figure 7 from Activating Inducible T cell Co-stimulator (ICOS) yields anti-tumor activity alone and in combination with anti-PD-1 checkpoint blockade

Healthy human donor CD4+ T cells were pre-activated with antiCD3/CD28 for 48 hours and then re-stimulated with plate-bound anti-CD3 in the presence of increasing concentrations of soluble or plate-bound feladilimab or isotype control for 72 hours. IFNg levels were then assessed from cell-free supernatants using Meso Scale Discovery (MSD)-based detection.</p

Supplementary Table 6 from Activating Inducible T cell Co-stimulator (ICOS) yields anti-tumor activity alone and in combination with anti-PD-1 checkpoint blockade

Example TIL marker expression phenotypes from clinical patient case studies of feladilimab monotherapy and in combination with pembrolizumab.</p

Supplementary Movie 1 from Activating Inducible T cell Co-stimulator (ICOS) yields anti-tumor activity alone and in combination with anti-PD-1 checkpoint blockade

Supplementary Movie 1</p

Supplementary Figure 1 from Activating Inducible T cell Co-stimulator (ICOS) yields anti-tumor activity alone and in combination with anti-PD-1 checkpoint blockade

Exemplar flow cytometry gating strategy.</p

Supplementary Figure 6 from Activating Inducible T cell Co-stimulator (ICOS) yields anti-tumor activity alone and in combination with anti-PD-1 checkpoint blockade

Feladilimab-mediated ICOS co-stimulation results in differential phenotypic changes and cytokine production in CD4+ non-Treg and Treg populations.</p

Supplementary Figure 5 from Activating Inducible T cell Co-stimulator (ICOS) yields anti-tumor activity alone and in combination with anti-PD-1 checkpoint blockade

Feladilimab induces phospho-AKT in ICOS-expressing Ba/F3 cells and cytokine production in PBMC from healthy donors and cancer patients.</p

Supplementary Table 4 from Activating Inducible T cell Co-stimulator (ICOS) yields anti-tumor activity alone and in combination with anti-PD-1 checkpoint blockade

Table S4</p